5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis

Inflammatory Bowel Diseases

Volumn 14, Issue 10, 2008, Pages 1341-1347

  Clapper, Margie L ^a   Gary, Monique A ^a   Coudry, Renata A ^a   Litwin, Samuel ^a   Chang, Wen Chi L ^a   Devarajan, Karthik ^a   Lubet, Ronald A ^b   Cooper, Harry S ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

5 Aminosalicylic acid; Colorectal neoplasia; Dextran sulfate sodium; Mouse model; Ulcerative colitis

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; MESALAZINE; CYCLOOXYGENASE 2; PTGS2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; ULCERATIVE COLITIS; ANIMAL; CHEMICALLY INDUCED DISORDER; COLITIS; DISEASE MODEL; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; PATHOLOGY;

ANIMALS; AZOXYMETHANE; COLITIS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MESALAMINE; MICE; RANDOM ALLOCATION;

EID: 57149109314     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20489     Document Type: Article

References (31)

1. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339-357.
2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet. 2002;359:331-340.
3. Brown WA, Farmer KC, Skinner SA, et al. 5-Aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci. 2000;45:1578-1584.
4. Reinacher-Schick A, Schoeneck A, Graeven U, et al. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis. 2003;24:443-451.
5. Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer. 1992;66:777-780.
6. Min mouse. Clin Cancer Res. 1999;5:855-863.
7. Suzuki S, Sakamoto S, Mitamura T, et al. Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis. In Vivo. 2000;14:463-466.
8. Cooper HS, Murthy S, Kido K, et al. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis. 2000;21:757-768.
9. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
10. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
11. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
12. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367-371.
13. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-1183.
14. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-153.
15. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
16. Rubin D, Djordjevic A, Huo D, et al. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:A-36.
17. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
18. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893.
19. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95.
20. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Review. Rev Gastroenterol Disord. 2004;4:104-117.
21. O'Dwyer PJ, Szarka CE, Yao K-S, et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest. 1996;98:1210-1217.
22. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
23. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109:883-893.
24. Nosho K, Yamamoto H, Adachi Y, et al. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer. 2005;92:1193-1200.
25. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451- 459.
26. Allgayer H. Review article. Mechanisms of action of mesalazine in preventing colorectal carcinoma in in?ammatory bowel disease. Aliment Pharmacol Ther. 2003;18(suppl 2):10-14.
27. Stolfi C, Fina D, Caruso R, et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008;75:668-676.
28. Greenfield SM, Punchard NA, Thompson RP. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid. Gut. 1991;32:1156-1159.
29. Weber CK, Liptay S, Wirth T, et al. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology. 2000;119:1209-1218.
30. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
31. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J Exp Med. 2005; 201:1205-1215.